Hospitalized Patients with Positive Antiphospholipid Antibodies Who Have Low Complement Levels Are at Increased Risk for Death-a Retrospective Cohort Study

Overview

Journal Lupus

Publisher Sage Publications

Specialty Rheumatology

Date 2023 Mar 23

PMID 36951167

Authors

Edward Itelman

Maxim Perelman

Natali Bivar

Daniella Kent

Adva Vaisman

Gad Segal

Liat Negru

Amir Dagan

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate whether low complement levels can predict worse outcomes in patients hospitalized with positive anti-phospholipid antibodies.

Methods: This was a retrospective cohort study. We obtained demographics, laboratory, and prognostic data of all consecutive patients hospitalized between 2007 and 2021, for whatever reason, with at least one positively abnormal anti-phospholipid antibody, who were also tested for complement levels (C3 or C4). We then compared the rates of long-term mortality, 1-year mortality, deep vein thrombosis, and pulmonary emboli between groups of low complement and normal complement levels. Multivariate analysis was used to control for levels of clinical and laboratory confounders.

Results: We identified 32,286 patients tested for anti-phospholipid antibodies. Of those patients, 6800 tested positive for at least one anti-phospholipid antibody and had a documented complement level. Significant higher mortality rates were found in the low complement group, with an odds ratio for mortality (OR 1.93 CI 1.63-2.27 < .001). Deep vein thrombosis and pulmonary emboli rates were similar. Multivariate analysis confirmed that low complement was an independent predictor for mortality after controlling for age, sex, dyslipidemia, chronic heart failure (CHF), chronic kidney disease (CKD), and anemia.

Conclusions: Our study results indicate that low complement is associated with significantly higher mortality rates in admitted patients with elevated levels of anti-phospholipid antibodies. This finding correlates with recent literature suggesting a vital role for complement activation in anti-phospholipid syndrome.

References

Pavoni V, Gianesello L, Horton A . Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?. J Thromb Thrombolysis. 2021; 52(2):542-552. PMC: 8109223. DOI: 10.1007/s11239-021-02470-y. View

Chaturvedi S, Braunstein E, Yuan X, Yu J, Alexander A, Chen H . Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2019; 135(4):239-251. PMC: 6978159. DOI: 10.1182/blood.2019003863. View

Bu C, Gao L, Xie W, Zhang J, He Y, Cai G . beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation. Arthritis Rheum. 2009; 60(2):559-68. PMC: 2965030. DOI: 10.1002/art.24262. View

Cervera R, Asherson R, Acevedo M, Gomez-Puerta J, Espinosa G, De La Red G . Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann Rheum Dis. 2004; 63(10):1312-7. PMC: 1754783. DOI: 10.1136/ard.2003.014175. View

Merashli M, Delgado Alves J, Gentile F, Ames P . Relevance of antiphospholipid antibodies in multiple sclerosis: A systematic review and meta analysis. Semin Arthritis Rheum. 2016; 46(6):810-818. DOI: 10.1016/j.semarthrit.2016.09.010. View

Breen K, Seed P, Parmar K, Moore G, Stuart-Smith S, Hunt B . Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thromb Haemost. 2012; 107(3):423-9. DOI: 10.1160/TH11-08-0554. View

Urbanus R, de Laat B . Antiphospholipid antibodies and the protein C pathway. Lupus. 2010; 19(4):394-9. DOI: 10.1177/0961203309360841. View

Devreese K, de Groot P, de Laat B, Erkan D, Favaloro E, Mackie I . Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost. 2021; 18(11):2828-2839. DOI: 10.1111/jth.15047. View

Lakos G, Favaloro E, Harris E, Meroni P, Tincani A, Wong R . International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum. 2011; 64(1):1-10. DOI: 10.1002/art.33349. View

10.

da Silva Saraiva S, Mazetto B, Quinteiro Tobaldine L, Colella M, De Paula E, Annichinno-Bizzachi J . The impact of antibody profile in thrombosis associated with primary antiphospholipid syndrome. Am J Hematol. 2017; 92(11):1163-1169. DOI: 10.1002/ajh.24875. View

11.

Svenungsson E, Antovic A . The antiphospholipid syndrome - often overlooked cause of vascular occlusions?. J Intern Med. 2020; 287(4):349-372. DOI: 10.1111/joim.13022. View

12.

Castillo-Martinez D, Torres Z, Amezcua-Guerra L, Pineda C . Are antiphospholipid antibodies just a common epiphenomenon or are they causative of immune-mediated coagulopathy in COVID-19?. Clin Rheumatol. 2021; 40(7):3015-3019. PMC: 8024929. DOI: 10.1007/s10067-021-05724-5. View

13.

Salmon J, Girardi G, Holers V . Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis. 2002; 61 Suppl 2:ii46-50. PMC: 1766708. DOI: 10.1136/ard.61.suppl_2.ii46. View

14.

Chaturvedi S, Brodsky R, McCrae K . Complement in the Pathophysiology of the Antiphospholipid Syndrome. Front Immunol. 2019; 10:449. PMC: 6426753. DOI: 10.3389/fimmu.2019.00449. View

15.

Ankri A, Bonmarchand M, Coutellier A, Herson S, Karmochkine M . Antiphospholipid antibodies are an epiphenomenon in HIV-infected patients. AIDS. 1999; 13(10):1282-3. DOI: 10.1097/00002030-199907090-00024. View

16.

Oku K, Nakamura H, Kono M, Ohmura K, Kato M, Bohgaki T . Complement and thrombosis in the antiphospholipid syndrome. Autoimmun Rev. 2016; 15(10):1001-4. DOI: 10.1016/j.autrev.2016.07.020. View

17.

Abdel-Wahab N, Tayar J, Faak F, Sharma G, Lopez-Olivo M, Yousif A . Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors. Blood Adv. 2020; 4(8):1746-1755. PMC: 7189282. DOI: 10.1182/bloodadvances.2020001557. View

18.

Tinti M, Carnevale V, Inglese M, Molinaro F, Bernal M, Migliore A . Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature. Clin Exp Med. 2019; 19(3):281-288. DOI: 10.1007/s10238-019-00565-8. View

19.

Petri M . Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun. 2000; 15(2):145-51. DOI: 10.1006/jaut.2000.0409. View

20.

Zikos T, Sokolove J, Ahuja N, Berube C . Eculizumab Induces Sustained Remission in a Patient With Refractory Primary Catastrophic Antiphospholipid Syndrome. J Clin Rheumatol. 2015; 21(6):311-3. DOI: 10.1097/RHU.0000000000000290. View